Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response

被引:27
作者
Brackman, Deanna J. [1 ]
Giacomini, Kathleen M. [1 ,2 ]
机构
[1] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA
关键词
CANCER RESISTANCE PROTEIN; CELL LUNG-CANCER; BREAST-CANCER; MULTIDRUG-RESISTANCE; ROSUVASTATIN PHARMACOKINETICS; GENETIC POLYMORPHISMS; ALZHEIMERS-DISEASE; TRANSPORTER ABCG2; RISK-FACTORS; PHASE-II;
D O I
10.1002/cpt.903
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Reverse translational research takes a bedside-to-bench approach, using sophisticated basic research to explain the biological mechanisms behind observed clinical data. For transporters, which play a role in human disease and drug response, this approach offers a distinct advantage over the typical translational research, which often falters due to inadequate in vitro and preclinical animal models. Research on ABCG2, which encodes the Breast Cancer Resistance Protein, has benefited immensely from a reverse translational approach due to its broad implications for disease susceptibility and both therapeutic and adverse drug response. In this review, we describe the success of reverse translational research for ABCG2 and opportunities for further studies.
引用
收藏
页码:233 / 242
页数:10
相关论文
共 50 条
  • [1] Design of inhibitors of BCRP/ABCG2
    Juvale, Kapil
    Wiese, Michael
    FUTURE MEDICINAL CHEMISTRY, 2015, 7 (12) : 1521 - 1527
  • [2] ABCG2/BCRP: Specific and Nonspecific Modulators
    Pena-Solorzano, Diana
    Stark, Simone Alexandra
    Koenig, Burkhard
    Augusto Sierra, Cesar
    Ochoa-Puentes, Cristian
    MEDICINAL RESEARCH REVIEWS, 2017, 37 (05) : 987 - 1050
  • [3] Regional expression of the BCRP/ABCG2 transporter in term human placentas
    Memon, Naureen
    Bircsak, Kristin M.
    Archer, Faith
    Gibson, Christopher J.
    Ohman-Strickland, Pamela
    Weinberger, Barry I.
    Parast, Mana M.
    Vetrano, Anna M.
    Aleksunes, Lauren M.
    REPRODUCTIVE TOXICOLOGY, 2014, 43 : 72 - 77
  • [4] Differential inhibition of murine Bcrpl/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C
    Gonzalez-Lobato, Lucia
    Real, Rebeca
    Prieto, Julio G.
    Alvarez, Ana I.
    Merino, Gracia
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 644 (1-3) : 41 - 48
  • [5] Interactions between riluzole and ABCG2/BCRP transporter
    Milane, Aline
    Vautier, Sarah
    Chacun, Helene
    Meininger, Vincent
    Bensimon, Gilbert
    Farinotti, Robert
    Fernandez, Christine
    NEUROSCIENCE LETTERS, 2009, 452 (01) : 12 - 16
  • [6] Expression of BCRP/ABCG2 Protein in Invasive Breast Cancer and Response to Neoadjuvant Chemotherapy
    Zhang, Yan Shou
    Yang, Chao
    Han, Lei
    Liu, Lei
    Liu, Yun Jiang
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (03) : 94 - 100
  • [7] Down-regulation of the placental BCRP/ABCG2 transporter in response to hypoxia signaling
    Francois, Lissa N.
    Gorczyca, Ludwik
    Du, Jianyao
    Bircsak, Kristin M.
    Yen, Elizabeth
    Wen, Xia
    Tu, Mei-Juan
    Yu, Ai-Ming
    Illsley, Nicholas P.
    Zamudio, Stacy
    Aleksunes, Lauren M.
    PLACENTA, 2017, 51 : 57 - 63
  • [8] The role of human ABC transporter ABCG2 (BCRP) in pharmacotherapy Preface
    Ishikawa, Toshihisa
    ADVANCED DRUG DELIVERY REVIEWS, 2009, 61 (01) : 1 - 2
  • [9] BCRP/ABCG2 confers anticancer drug resistance without covalent dimerization
    Shigeta, Junichi
    Katayama, Kazuhiro
    Mitsuhashi, Junko
    Noguchi, Kohji
    Sugimoto, Yoshikazu
    CANCER SCIENCE, 2010, 101 (08) : 1813 - 1821
  • [10] Physiological and pharmacological roles of ABCG2 (BCRP): Recent findings in Abcg2 knockout mice
    Vlaming, Maria L. H.
    Lagas, Jurjen S.
    Schinkel, Alfred H.
    ADVANCED DRUG DELIVERY REVIEWS, 2009, 61 (01) : 14 - 25